The global peptide therapeutics market report provides detailed analysis, market size, and forecast for therapeutic peptides approved for various indications. The market is studied from four major perspectives: applications, route of administration, marketing status, and geography.
Application segments of the global peptide therapeutics market have been further sub-segmented by major branded peptide drugs approved by regulatory authorities across the globe. Various applications considered in the report include metabolic disorders, hematological disorders, cancer, cardiovascular disorders, central nervous system disorders, infection, gastrointestinal disorders, respiratory disorders, acromegaly, and others.
Market size and forecast for leading drugs such as Angiomax, Copaxone, Forteo, Sandostatin, Velcade, Victoza, and Zoladex has been included along with in-depth market analysis. Segmentation by marketing status explains the impact of generic drugs on the overall peptide therapeutics market.
Further, market segmentation of peptide drugs by route of administration provides quantitative insights into the growing demand for convenient methods for peptide drug administration. Details on peptide drug approvals, patent expiry, mergers, acquisitions, strategic agreements, disease prevalence and other major events have been included in respective market segments.
The global peptide therapeutics market report provides market estimation and forecast for more than fifteen branded peptide drugs in the market. Further, the market is also segmented by major geographical regions, which include North America, Europe, Asia Pacific and Rest of the World.
A list of pipeline drugs has also been provided in the report. This list includes potential peptide drugs in phases I, II, and III of clinical development.
Read more: http://www.whatech.com/market-research-reports/press-release/medical/57041-new-report-explores-the-peptide-therapeutics-market-that-is-expected-to-reach-usd-23-7-billion-globally-in-2020